{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:21:20Z","timestamp":1787721680530,"version":"build-2784847793"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM25\/00250, CM25\/00243, JR24\/00034"],"award-info":[{"award-number":["CM25\/00250, CM25\/00243, JR24\/00034"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bispecific antibodies (BsAbs) are transformative therapies for multiple myeloma (MM) and B-cell malignancies. Cytomegalovirus (CMV) infection has been reported as a potential complication of unclear clinical magnitude.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of MM patients treated with BsAbs at our institution (2020\u20132025), alongside a systematic review and meta-analysis of clinical trials and observational studies evaluating BsAbs for MM, B-cell lymphoma, and acute lymphoblastic leukemia. Study outcomes included clinically significant CMV infection (csCMVi), any CMV DNAemia, and CMV disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our cohort included 98 BsAb therapy courses (74.5% anti-B-cell maturation antigen [BCMA]) with a median follow-up of 10.4 months. Cumulative incidence rates for csCMVi and CMV disease were 9.2% (9\/98) and 3.1% (3\/98), respectively. Factors associated with csCMVi at the univariable level were poorer functional status, prior allogeneic hematopoietic stem cell transplantation (allo-HSCT), grade 4 neutropenia, and grade \u22653 cytokine release syndrome (CRS). The meta-analysis (23 studies plus our single-center cohort comprising 2,956 BsAb courses) revealed a pooled cumulative incidence rates of 9% (95% confidence interval [CI]: 4\u201315%; I\n                      <jats:sup>2<\/jats:sup>\n                      96.11%) for csCMVi and 1% (95% CI: 0\u20132%; I\n                      <jats:sup>2<\/jats:sup>\n                      69.78%) for CMV disease. Incidence was notably higher in studies applying routine CMV DNAemia monitoring and with anti-BCMA agents.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The occurrence of csCMVi or CMV disease during the course of BsAb therapy for MM or B-cell malignancies is uncommon, arguing against routine CMV DNAemia monitoring or antiviral prophylaxis. Prevention approaches, however, may be warranted in patients receiving anti-BCMA BsAbs with additional risk factors such as allo-HSCT or severe CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420251162657.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1918863","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:43:29Z","timestamp":1787719409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Eduardo","family":"Aparicio-Minguij\u00f3n","sequence":"first","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rodr\u00edguez-Goncer","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]},{"name":"Department of Medicine, School of Medicine, Universidad Complutense","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"P\u00e9rez-Jacoiste As\u00edn","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]},{"name":"Department of Medicine, School of Medicine, Universidad Complutense","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Bartolom\u00e9 Herguedas","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Hospital Universitario \u201c12 de Octubre\u201d","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Bo\u00e1n","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo Jes\u00fas","family":"S\u00e1ez Mar\u00edn","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]},{"name":"Department of Hematology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Aguado","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]},{"name":"Department of Medicine, School of Medicine, Universidad Complutense","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Hospital Universitario \u201c12 de Octubre\u201d, Instituto de Investigaci\u00f3n Sanitaria Hospital \u201c12 de Octubre\u201d (imas12)","place":["Madrid, Spain"]},{"name":"Department of Medicine, School of Medicine, Universidad Complutense","place":["Madrid, Spain"]},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17805","article-title":"The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies","volume":"196","author":"Swan","year":"2022","journal-title":"Br J Haematol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100810","article-title":"Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap","volume":"49","author":"Longhitano","year":"2021","journal-title":"Blood Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2024.02.023","article-title":"Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.08.014","article-title":"Predicators and outcomes of cytomegalovirus reactivation in chimeric antigen receptor T-cell therapy: a systematic review","volume":"25","author":"Khan","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/v17010133","article-title":"Herpesvirus infections after chimeric antigen receptor T-cell therapy and bispecific antibodies: a review","volume":"17","author":"Sassine","year":"2025","journal-title":"Viruses"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab safety profile in patients with relapsed\/refractory B-cell non-Hodgkin lymphoma: clinical management experience from a pivotal phase I\/II trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20\u00d7CD3 bispecific antibody in patients with CD20-positive B-cell Malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC\u20101 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1200\/JCO.2013.48.7934","article-title":"International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B21","unstructured":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses\n          \n          \n            \n              Wells\n              GA\n            \n            \n              Shea\n              B\n            \n            \n              O\u2019Connell\n              D\n            \n            \n              Peterson\n              J\n            \n            \n              Welch\n              V\n            \n            \n              Losos\n              M"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2023-180013","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-cell maturation antigen (BCMA) \u00d7 CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib\u2013Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults","volume":"383","author":"Fo\u00e0","year":"2020","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2025.100097","article-title":"Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamab","volume":"2","author":"Pei","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2025.40.e86","article-title":"Incidence and characteristics of infectious complications in multiple myeloma patients treated with bispecific antibodies","volume":"40","author":"Park","year":"2025","journal-title":"J Korean Med Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41408-025-01282-0","article-title":"Effect of intravenous immunoglobulin (IVIG) supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma","volume":"15","author":"Mohan","year":"2025","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-024-01043-5","article-title":"Comparison of infectious complications with BCMA-directed therapies in multiple myeloma","volume":"14","author":"Nath","year":"2024","journal-title":"Blood Cancer J"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7048","article-title":"Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: real\u2010world evidence from Sweden","volume":"13","author":"Uttervall","year":"2024","journal-title":"Cancer Med"},{"key":"B32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","article-title":"Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288187","article-title":"Infection risk in 158 patients with relapsed\/refractory multiple myeloma treated with bispecific antibodies: a single-center experience","volume":"111","author":"Cani","year":"2026","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","article-title":"Infectious complications of bispecific antibody therapy in patients with multiple myeloma","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/tid.70138","article-title":"Cytomegalovirus infection after chimeric antigen receptor T\u2010cell therapy or bispecific antibody treatment for hematologic Malignancies","volume":"27","author":"Han","year":"2025","journal-title":"Transpl Infect Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix325","article-title":"Dasatinib use and risk of cytomegalovirus reactivation after allogeneic hematopoietic-cell transplantation","volume":"65","author":"Prestes","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012922","article-title":"Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy","volume":"8","author":"Lin","year":"2024","journal-title":"Blood Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae422","article-title":"Cytomegaloviral infections in recipients of chimeric antigen receptor T-cell therapy: an observational study with focus on oncologic outcomes","volume":"11","author":"Khawaja","year":"2024","journal-title":"Open Forum Infect Dis"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:43:40Z","timestamp":1787719420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1918863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":41,"alternative-id":["10.3389\/fonc.2026.1918863"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1918863","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1918863"}}